Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
M Andreeff, KR Kelly, K Yee, S Assouline, R Strair… - Clinical Cancer …, 2016 - AACR
Clinical Cancer Research, 2016•AACR
Purpose: RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of
the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study
of RG7112 in patients with hematologic malignancies was conducted. Experimental Design:
Primary study objectives included determination of the dose and safety profile of RG7112.
Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as
TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were …
the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study
of RG7112 in patients with hematologic malignancies was conducted. Experimental Design:
Primary study objectives included determination of the dose and safety profile of RG7112.
Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as
TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were …
Abstract
Purpose: RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted.
Experimental Design: Primary study objectives included determination of the dose and safety profile of RG7112. Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL). Some Stratum A patients were treated at the MTD to assess clinical activity.
Results: RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B). All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported. Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure. Antileukemia activity was observed in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response. Exploratory analysis revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients. Two patients with TP53 mutations exhibited clinical activity. p53 target genes were induced only in TP53 wild-type leukemic cells. Baseline expression levels of MDM2 correlated positively with clinical response.
Conclusions: RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies. Clin Cancer Res; 22(4); 868–76. ©2015 AACR.
AACR